Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.430
+0.010 (0.70%)
At close: Aug 1, 2025, 4:00 PM
1.448
+0.018 (1.27%)
After-hours: Aug 1, 2025, 7:59 PM EDT

Company Description

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.

Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial.

Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute.

The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals logo
CountryUnited States
Founded1979
IPO DateFeb 12, 1998
IndustryBiotechnology
SectorHealthcare
Employees134
CEOJacqueline Shea

Contact Details

Address:
660 West Germantown Pike, Suite 110
Plymouth Meeting, Pennsylvania 19462
United States
Phone267 440 4200
Websiteinovio.com

Stock Details

Ticker SymbolINO
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001055726
CUSIP Number45773H201
ISIN NumberUS45773H4092
Employer ID33-0969592
SIC Code2834

Key Executives

NamePosition
Dr. Jacqueline E. Shea Ph.D.Chief Executive Officer, President and Director
Peter D. KiesChief Financial Officer
Dr. Michael Sumner M.D.Chief Medical Officer
Dr. Laurent M. Humeau Ph.D.Chief Scientific Officer and Chairman of the Scientific Advisory Board
Thomas HongManager of Investor Relations
Robert L. Crotty J.D.General Counsel, Corporate Secretary and Chief Compliance Officer
E. J. Brandreth MBASenior Vice President of Quality Assurance
Dr. Jeffrey SkolnikSenior Vice President of Clinical Development
Robert J. Juba Jr.Senior Vice President of Biological Manufacturing and Clinical Supply Management
Shawn D. Bridy M.A., M.B.A.Senior Vice President of Business Development

Latest SEC Filings

DateTypeTitle
Jul 17, 2025SCHEDULE 13G/AFiling
Jul 7, 20258-KCurrent Report
Jul 3, 2025424B5Filing
Jul 2, 2025424B5Filing
May 22, 20258-KCurrent Report
May 14, 2025SCHEDULE 13G/AFiling
May 13, 20258-KCurrent Report
May 13, 202510-QQuarterly Report
Apr 30, 2025SCHEDULE 13GFiling
Apr 17, 2025SCHEDULE 13G/AFiling